We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 1,027

Paediatric extensions to SPCs

  • Taylor Wessing
  • -
  • European Union
  • -
  • October 30 2013

In addition to monopoly protection in the form of a patent and a supplementary protection certificate (SPC), medicinal products may also be protected

EU daily updates: foodconsumer policypharmaceuticals - 19112007

  • Hogan Lovells
  • -
  • European Union
  • -
  • November 19 2007

Commission Decision of 8 November 2007 amending Decision 2007102EC adopting the work plan for 2007 for implementation of the programme of Community action in the field of public health (2003 to 2008), including the annual work programme for grants

European Commission adopts decision to establish eHealth network

  • Mills & Reeve LLP
  • -
  • European Union
  • -
  • February 13 2012

The European Commission has adopted a decision to establish a voluntary eHealth network, pursuant to Article 14 of the Directive on Patients’ Rights in Cross-Border Healthcare (201124EU

Patent settlement agreements come under Commission scrutiny

  • Nabarro LLP
  • -
  • European Union
  • -
  • January 28 2010

Hot on the heels of the pharmaceutical sector inquiry in 2009 and the formal proceedings opened against Lundbeck, the European Commission revealed that it sent requests to a number of large pharmaceutical companies for copies of recent patent settlement agreements

Right to peaceful enjoyment of possessions: Malik v United Kingdom 13.03.12

  • Kennedys Law LLP
  • -
  • European Union, United Kingdom
  • -
  • April 30 2012

Primary care trust (PCT) did not violate Article 1 of Protocol 1 of the European Convention on Human Rights (right to “peaceful enjoyment of possessions”), by suspending general practitioner from his practice

Medeva's SPC applications: the Court of Appeal refers questions to the ECJ

  • Wragge Lawrence Graham & Co LLP
  • -
  • European Union, United Kingdom
  • -
  • July 7 2010

The Court of Appeal has decided to refer a series of questions on the interpretation of the SPC Regulation to the Court of Justice of the European Union (CJEU) relating to the requirement that a "product is protected by a basic patent"

Employees can claim holidays lost due to illness

  • Kennedys Law LLP
  • -
  • European Union, Spain
  • -
  • November 3 2009

The European Court of Justice ("ECJ") has ruled that, where a worker’s pre-arranged annual leave coincides with a period of sick leave, the worker is entitled to take that period of annual leave at a later date

Federfarma files complaint with prosecutor over parallel trade

  • Baker & McKenzie
  • -
  • European Union
  • -
  • August 19 2013

In July, the National Federation of Pharmacy Owners (Federfarma) lodged a complaint with the Rome public prosecutor's office decrying what it

Belgian EU presidency proposes labeling requirements, registry for nanomaterials

  • Shook Hardy & Bacon LLP
  • -
  • European Union
  • -
  • September 17 2010

The Belgian Presidency of the Council of the European Union (EU) has issued five regulatory proposals to respond to consumer and safety needs regarding nanomaterials found in mass-produced consumer products including food, electronics and cosmetics

European General Court upholds findings of abuse of dominant position by AstraZeneca for misusing the SPC and marketing authorising systems

  • Bird & Bird
  • -
  • European Union
  • -
  • July 28 2010

The European General Court issued its judgment on 1 July 2010 on AstraZeneca's appeal against the European Commission's decision adopted on 15 June 2005 fining AstraZeneca ("AZ") EUR 60 million for abuse of dominant position through misuse of the patent system to obtain supplementary protection certificates (SPCs) and misuse of the pharmaceutical regulatory system by selective withdrawal of certain marketing authorisations